1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Wang, Y. Henz, M.E. Gallagher, N.L.F. Chai, S. Yan, L.Z. Gibbs, A.C. Stiles, M.E. Wishart, D.S. Vederas, J.C. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 38 15438 15447 10.1021/bi991351x 10569926 Solution structure of carnobacteriocin B2 and implications for structure-activity relationships among type IIa bacteriocins from lactic acid bacteria. 1999 10.2210/pdb1cw6/pdb pdb_00001cw6 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 3937.323 TYPE IIA BACTERIOCIN LEUCOCIN A LEUCOCIN A-UAL 187 1 nat polymer no no KYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW KYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Leuconostoc sample 1244 Leuconostoc gelidum database_2 pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 1999-09-08 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-16 _database_2.pdbx_DOI _database_2.pdbx_database_accession 2LEU CONTAINS THE SAME PEPTIDE WITH A STRUCTURE BASED ON FEWER CONTRAINTS. RCSB Y RCSB 1999-08-25 REL REL THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES. THE STRUCTURE WAS DETERMINED USING TRIPLE-RESONANCE NMR SPECTROSCOPY. STRUCTURES WITH ACCEPTABLE COVALENT GEOMETRY,STRUCTURES WITH FAVORABLE NON- BOND ENERGY,STRUCTURES WITH THE LEAST RESTRAINT VIOLATIONS,STRUCTURES WITH THE LOWEST ENERGY 18 18 2D NOESY 0 2.8 AMBIENT 298 K THE REFINED STRUCTURES ARE BASED ON A TOTAL OF 434 INTERPROTON DISTANCE RESTRAINTS, 27 3JHNHA COUPLING CONSTANT RESTRAINTS, AND 136 PROTON CHEMICAL SHIFT RESTRAINTS simulated annealing 9 closest to the average 2MM LEUCOCIN A IN 90% TFE-D3,10% H2O BRUNGER structure solution X-PLOR 3.85 VRIAN processing VNMR 5.1 BRUNGER refinement X-PLOR 3.85 500 Varian UNITY LYS 1 n 1 LYS 1 A TYR 2 n 2 TYR 2 A TYR 3 n 3 TYR 3 A GLY 4 n 4 GLY 4 A ASN 5 n 5 ASN 5 A GLY 6 n 6 GLY 6 A VAL 7 n 7 VAL 7 A HIS 8 n 8 HIS 8 A CYS 9 n 9 CYS 9 A THR 10 n 10 THR 10 A LYS 11 n 11 LYS 11 A SER 12 n 12 SER 12 A GLY 13 n 13 GLY 13 A CYS 14 n 14 CYS 14 A SER 15 n 15 SER 15 A VAL 16 n 16 VAL 16 A ASN 17 n 17 ASN 17 A TRP 18 n 18 TRP 18 A GLY 19 n 19 GLY 19 A GLU 20 n 20 GLU 20 A ALA 21 n 21 ALA 21 A PHE 22 n 22 PHE 22 A SER 23 n 23 SER 23 A ALA 24 n 24 ALA 24 A GLY 25 n 25 GLY 25 A VAL 26 n 26 VAL 26 A HIS 27 n 27 HIS 27 A ARG 28 n 28 ARG 28 A LEU 29 n 29 LEU 29 A ALA 30 n 30 ALA 30 A ASN 31 n 31 ASN 31 A GLY 32 n 32 GLY 32 A GLY 33 n 33 GLY 33 A ASN 34 n 34 ASN 34 A GLY 35 n 35 GLY 35 A PHE 36 n 36 PHE 36 A TRP 37 n 37 TRP 37 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N THR 10 A N THR 10 A O GLY 13 A O GLY 13 1 A A O H TRP PHE 18 22 1.47 2 A A O H TRP PHE 18 22 1.56 2 A A O H HIS SER 8 15 1.59 2 A A O N THR SER 10 12 2.17 3 A A O H TRP PHE 18 22 1.54 3 A A O H HIS SER 8 15 1.59 4 A A O H HIS SER 8 15 1.37 4 A A O H TRP PHE 18 22 1.40 5 A A O H TRP PHE 18 22 1.43 5 A A O H HIS SER 8 15 1.49 6 A A O H TRP PHE 18 22 1.49 7 A A O H TRP PHE 18 22 1.46 7 A A O H HIS SER 8 15 1.56 8 A A O H TRP PHE 18 22 1.53 8 A A O H HIS SER 8 15 1.53 9 A A O H TRP PHE 18 22 1.50 10 A A O H TRP PHE 18 22 1.50 10 A A O H HIS SER 8 15 1.50 11 A A O H TRP PHE 18 22 1.49 11 A A O H HIS SER 8 15 1.59 12 A A O H TRP PHE 18 22 1.41 13 A A O H TRP PHE 18 22 1.52 14 A A O H TRP PHE 18 22 1.39 15 A A O H TRP PHE 18 22 1.50 16 A A O H TRP PHE 18 22 1.45 16 A A O H HIS SER 8 15 1.56 17 A A O H TRP PHE 18 22 1.56 17 A A O H THR SER 10 12 1.57 17 A A O H HIS SER 8 15 1.59 17 A A O N THR SER 10 12 2.08 18 A A O H TRP PHE 18 22 1.40 18 A A O H HIS SER 8 15 1.57 1 A TYR 3 -109.73 40.34 1 A ASN 5 -145.80 52.42 1 A LYS 11 36.10 34.77 1 A SER 12 74.04 47.00 1 A TRP 18 64.07 -65.14 1 A ASN 34 66.11 -61.12 1 A PHE 36 55.64 80.77 2 A TYR 3 -103.26 41.17 2 A ASN 5 -148.14 39.69 2 A LYS 11 22.55 -61.46 2 A TRP 18 65.55 -70.49 3 A LYS 11 77.73 -84.27 3 A SER 12 -153.44 22.68 3 A TRP 18 65.90 -60.71 3 A PHE 36 72.29 -155.83 4 A ASN 5 -148.01 38.94 4 A CYS 9 -119.39 78.21 4 A LYS 11 83.21 -89.68 4 A SER 12 -149.61 20.79 4 A TRP 18 17.21 -64.93 4 A PHE 36 77.42 112.22 5 A ASN 5 -146.98 33.25 5 A LYS 11 87.57 -85.38 5 A SER 12 -150.49 31.89 5 A TRP 18 19.51 -69.02 5 A ASN 34 -150.93 -46.86 5 A PHE 36 -162.21 35.43 6 A TYR 3 -105.77 42.20 6 A ASN 5 -146.47 29.66 6 A TRP 18 70.17 -59.47 7 A ASN 5 -107.55 50.71 7 A CYS 9 -114.16 79.21 7 A LYS 11 83.05 -87.26 7 A SER 12 -150.92 22.63 7 A TRP 18 64.94 -63.25 7 A ASN 34 -152.22 46.15 8 A TYR 3 -106.06 40.53 8 A ASN 5 -147.91 48.17 8 A CYS 9 -113.23 65.24 8 A LYS 11 29.11 101.32 8 A SER 12 82.02 -46.48 8 A TRP 18 62.41 -63.43 9 A ASN 5 -146.48 45.95 9 A TRP 18 66.31 -64.94 9 A PHE 36 -163.12 45.39 10 A ASN 5 -146.48 33.57 10 A LYS 11 92.42 -85.88 10 A SER 12 -151.44 26.50 10 A TRP 18 68.26 -63.92 10 A PHE 36 76.59 -1.11 11 A ASN 5 -148.89 48.14 11 A LYS 11 47.08 -66.42 11 A SER 12 -154.59 17.08 11 A TRP 18 66.24 -69.58 12 A ASN 5 -148.11 47.48 12 A TRP 18 66.96 -62.61 12 A ASN 34 -98.14 -68.43 13 A TYR 3 -132.55 -31.71 13 A ASN 5 -101.34 49.97 13 A TRP 18 68.63 -60.82 13 A PHE 36 -161.69 117.59 14 A ASN 5 -146.36 49.21 14 A CYS 9 -106.99 75.97 14 A LYS 11 85.59 -87.96 14 A SER 12 -152.06 21.80 14 A TRP 18 68.16 -62.54 14 A ALA 30 -79.31 -78.66 14 A ASN 31 43.96 71.60 14 A PHE 36 -161.94 33.61 15 A ASN 5 -145.54 40.83 15 A TRP 18 65.47 -64.85 16 A ASN 5 -147.06 32.18 16 A CYS 9 -116.09 77.81 16 A LYS 11 39.40 35.04 16 A SER 12 73.39 33.02 16 A TRP 18 68.26 -66.27 16 A ASN 34 -152.06 -42.37 16 A PHE 36 -161.06 70.87 17 A ASN 5 -146.82 36.61 17 A LYS 11 25.08 -54.44 17 A TRP 18 67.82 -59.73 17 A ASN 34 45.33 76.95 17 A PHE 36 -163.31 -78.85 18 A ASN 5 -145.22 33.99 18 A CYS 9 -106.11 78.10 18 A LYS 11 37.27 -85.09 18 A SER 12 -149.30 21.31 18 A TRP 18 74.86 -68.92 18 A ASN 34 53.74 95.76 18 A PHE 36 50.67 173.56 REFINED SOLUTION STRUCTURE OF LEUCOCIN A 1 N N A TRP 18 A TRP 18 HELX_P A ALA 30 A ALA 30 1 1 13 disulf 2.030 A CYS 9 A SG CYS 9 1_555 A CYS 14 A SG CYS 14 1_555 TOXIN ANTIMICROBIAL PEPTIDE, BACTERIOCIN, TOXIN LCCA_LEUGE UNP 1 P34034 25 61 1CW6 1 37 P34034 A 1 1 37 2 anti-parallel A HIS 8 A HIS 8 A THR 10 A THR 10 A GLY 13 A GLY 13 A SER 15 A SER 15 1 P 1